ODAC Takes Up Comparative Efficacy, Safety In Review Of Pfizer Inlyta
Executive Summary
The Oncologic Drugs Advisory Committee seemed to have a comparative efficacy standard in mind when it unanimously recommended the drug for approval at its Dec. 7 meeting, bypassing FDA's instructions not to consider the results against the control arm.